Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pulmatrix Inc.

This article was originally published in Start Up

Executive Summary

Originally intent on developing a contagion-prevention product for biodefense, Pulmatrix Inc. now has much larger ambitions. The company believes its new technologies for formulating drugs as dry powders and delivering them via inhalers will make its lead respiratory drug candidate more convenient and potent. Pulmatrix also sees the methods as a discovery engine likely to give rise to partnerships and branded generics.
Advertisement

Related Content

Pulmatrix Takes $14 Mil. From Insiders, Sharpens Focus On Dry-Powder Inhaler Drug
Pulmatrix Takes $14 Mil. From Insiders, Sharpens Focus On Dry-Powder Inhaler Drug
Start-Up Previews
Protectimmun GMBH
Pearl Therapeutics Inc.
Respiratory Therapies: Moving Beyond Symptomatic Relief
Respiratory Therapies: Moving Beyond Symptomatic Relief

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC092133

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel